Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iberogast
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Iberogast (also known as STW 5) is a clinically proven, multi-target herbal preparation used for the treatment of functional gastrointestinal disorders, most notably functional dyspepsia and irritable bowel syndrome (IBS). It is a fixed combination of nine hydroethanolic extracts: *Iberis amara*, *Angelica archangelica*, *Matricaria recutita*, *Carum carvi*, *Silybum marianum*, *Melissa officinalis*, *Mentha x piperita*, *Chelidonium majus*, and *Glycyrrhiza glabra*. The drug exhibits a dual effect on gastrointestinal motility, acting as a prokinetic in the hypomotile antrum (via 5-HT4 agonism and muscarinic stimulation) and as a spasmolytic in the hypermotile corpus (via 5-HT3 antagonism and other pathways). Additionally, Iberogast demonstrates anti-inflammatory, antioxidant, and mucosal protective properties, and it reduces visceral hypersensitivity by modulating intestinal afferent sensitivity. Originally developed by Steigerwald Arzneimittelwerk, it is now a key product in Bayer's consumer health portfolio.
- Brand names
- Iberogast
- Other names
- STW 5STW5STW-5Iberis amara combination
02
Targets
HTR4 (5-Hydroxytryptamine receptor 4)CHRM3 (M3)
Beyond the preview
Go deeper on Iberogast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iberogast.